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The role of genomic instability and proliferative activity for development of distant metastases in breast cancer was analysed, and the
relative contribution of these two risk factors was quantified. A detailed quantitative comparison was performed between Ki67 and
cyclin A as proliferative markers. The frequency of Ki67 and cyclin A-positive cells was scored in the same microscopic areas in 428
breast tumours. The frequency of Ki67-positive cells was found to be highly correlated with the frequency of cyclin A-positive cells,
and both proliferation markers were equally good to predict risk of distant metastases. The relative contribution of degree of
aneuploidy and proliferative activity as risk markers for developing distant metastases was studied independently. Although increased
proliferative activity in general was associated with an increased risk of developing distant metastases, ploidy level was found to be an
independent and even stronger marker when considering the group of small (T1) node negative tumours. By combining proliferative
activity and ploidy level, a large group of low risk breast tumours (39%) could be identified in which only a few percentage of the
tumours (5%) developed distant metastases during the 9-year follow-up time period.
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Numerous studies published during the last decades have
clearly shown that genomic instability in terms of degree of
aneuploidy (D- or A-type, Forsslund and Zetterberg, 1990;
Forsslund et al, 1996) and chromosomal rearrangements is closely
related to tumour development and tumour progression. Breast
tumours of the D-type generally progressed more slowly, on
the average four times, and were clinically much less aggressive
than their highly aneuploid, genomically unstable counterparts
of the A-type (Auer et al, 1980; Cornelisse et al, 1987; Fallenius
et al, 1988a; Kronenwett et al, 2006). Chromosomal rearrange-
ments in terms of deletions, duplications and amplifications,
as studied by comparative genomic hybridization (CGH), were
found to be much more frequent in the highly aneuploid
breast tumours than in the diploid ones (Kallioniemi et al, 1994;
Ried et al, 1995; Blegen et al, 2001). High-resolution micro-
array-based CGH data have verified and extended these find-
ings, and identified chromosomal regions and novel specific
patterns and degree of rearrangements related to aggressive tumour
behaviours (Hicks et al, 2006). Taken together, these data clearly
indicate that genomic instability is an important factor for tumour
development and progression including distant metastases.
In addition to genomic instability, proliferative activity is a
general property to be considered in the progression of tumours.
Tumour cell proliferation has been widely investigated in breast
cancer for its association with neoplastic growth, progression,
metastatic potential, survival and response to chemotherapy
(van Diest et al, 2004; Colozza et al, 2005; Beresford et al, 2006).
Proliferative activity could be assessed through immunohisto-
chemical procedures detecting proliferation-associated antigens,
such as Ki67 (Gerdes, 1990), or cell-cycle-specific proteins such as
cyclin A (Hunt, 1991; Sherr, 1993; Nurse, 1994). Various studies
have shown that a high expression of Ki67 or cyclin A is correlated
with a worse prognosis in breast cancer (Bukholm et al, 2001;
Kuhling et al, 2003; Poikonen et al, 2005; Baldini et al, 2006; Ahlin
et al, 2007; de Azambuja et al, 2007; Railo et al, 2007). However,
evidence has also been obtained that the prognostic value of
proliferation markers varies significantly depending on clinical
characteristics of the tumour disease, for example, lymph node
status (Jalava et al, 2006; Trere et al, 2006). Thus, to obtain more
detailed information regarding the prognostic contribution of
proliferation markers in breast cancer, patients have to be
subgrouped according to clinical features, for example, tumour
size and lymph node status.
The specific aim of this study was to investigate and compare in
the same individual tumours, the relative influence of genomic
instability and proliferative activity as risk factors for development
of distant metastases in breast cancer. As one aspect of genomic
instability, the degree of aneuploidy was quantified, and the
tumours were separated in the two groups (A or D) with respect to
ploidy level. The proliferative activity was analysed by immuno-
histochemistry using antibodies against Ki67 and cyclin A. An
important methodological aspect of this paper was the direct
quantitative comparison performed between the Ki67 analysis and
the cyclin A analysis in the same tumour areas. By combining
proliferative activity and ploidy level, a relatively large group of Received 14 March 2008; revised 12 June 2008; accepted 12 June 2008
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slow-risk breast tumours (39%) could be identified in which only a
few percentage of the tumours (5%) developed distant metastases
during the 9-year follow-up time period. In the remaining 61% of
the breast cancers, 35% developed distant metastases during the
same follow-up time period.
MATERIALS AND METHODS
Tumour samples
This study was based on the data of 428 patients with breast
cancer analysed at the department of Oncology–Pathology,
Karolinska University Hospital, Solna, at the time of diagnosis
(1997–1998). All histological specimens were routinely Ki67- and
cyclin A-stained. In the 428 cases, 378 patients available with
clinical data were followed up from diagnosis until death or
survivors for at least 9 years. All tumours were classified according
to the World Health Organization (1981) and graded on the basis
of the recommendations of Elston and Ellis (1991). Permission to
analyse the samples and correlate the results to patient data was
obtained by the Ethical Committee Nord, Karolinska Institutet
(Dnr 00-186). The tumour samples were fixed in 4% phosphate-
buffered formaldehyde directly after operation and paraffin-
embedded. From each specimen, 10 contiguous sections were
prepared and used for HE staining and immunohistochemistry
(thickness 4mm).
Immunohistochemistry
The sections were deparaffinized with xylene, rehydrated through
a graded alcohol series and microwaved at 500W for 2 5min in
10mM citrate buffer (pH 6.0). After rinsing in Tris-buffered saline
(TBS, pH 7.6), sections were treated with 3% hydrogen peroxide in
methanol to exhaust endogenous peroxidase activity followed by
normal horse serum (1:20 dilution) in 0.1M PBS (pH 6.0), and
then incubated overnight with the monoclonal primary antibodies
diluted in 1% (wt/vol) bovine serum albumin and visualized
by standard avidin–biotin–peroxidase complex technique
(Vector Laboratories, Burlingame, CA, USA). Counterstaining
was performed with Mayer’s haematoxylin. The antibodies used
were as follows: MIB-1 (antibody against the nuclear proliferation-
associated antigen Ki67, Immunotech SA, Marseille, France),
dilution 1:150; NCL-cyclin A (Cyclin A monoclonal antibody,
Novocastra Laboratories Ltd, Claremont Place, Newcastle upon
Tyne, UK), dilution 1:100.
Evaluation of immunoreactivity scores
By comparison with the haematoxylin-and-eosin-stained sections,
images of the same morphology areas expressing Ki67 and cyclin A
were taken by digital camera in at least 5–14 high-power fields
(10 40 magnification). The percentage of positive cells was
measured by two experienced pathologists blinded to each other. A
minimum of 1000 tumour cells were counted. Only distinct nuclear
staining was accepted as a positive reaction for both markers,
whereas all cells with simultaneous nuclear and cytoplasmic cyclin
A staining were regarded as positive for cyclin A.
Image cytometry
Nuclear DNA was measured by image cytometry on Feulgen-
stained imprints as previously described (Auer et al, 1980). DNA
histograms were interpreted according to a modified subjective
method. The normal control cells were given the value 2c, denoting
the normal diploid DNA content, and all tumour-cell DNA values
were expressed in relation to that. The histograms were divided
into two groups. Cases with a major peak near the 2c region
(1.8c–2.2c), and o10% cells exceeding 2.2c were denoted diploid.
DNA profiles with a stem line outside the diploid and tetraploid
region and distinctly scattered DNA values exceeding the
tetraploid region (3.8c–4.2c) were classified as aneuploid.
Furthermore, the S-phase fraction (SPF) was measured on the
basis of the DNA distribution patterns (Falkmer et al, 1990).
Statistical analysis
Statistical analyses were performed using the SPSS for Windows
version 11. The correlation between cyclin A, Ki67 and SPF were
evaluated by Spearman’s rank correlation test and the linear
correlation test. Fisher’s exact test was used to compare the
difference between non-continuous variable. Cut-off points of Ki67
and cyclin A in patients with distant metastases were calculated by
ROC curves quantitative analysis, and contribution of the risk
factors to distant metastases was determined by multivariate
analysis with logistic regression. P-valueo0.05 was considered to
be statistically significant.
RESULTS
To obtain accurate information about proliferative activity, two
independent markers Ki67 and cyclin A were used, and a direct
quantitative comparison between these two markers was per-
formed. An important methodological aspect of the approach used
in this paper is that the Ki67 and the cyclin A analyses were carried
out on identical microscopic areas (5–14 areas in each corres-
ponding tumour) of all of the 428 tumours. This gives particular
strength to the accuracy of the quantitative data obtained on
proliferative activity.
Figure 1 illustrates immunostaining of two tumours, one slowly
proliferating near-diploid, D-tumour (Figure 1A and C) and one
rapidly proliferating clearly aneuploid, A-tumour (Figure 1B and D).
The number of Ki67-positive cells is low (4%) in the D-tumour
(Figure 1A) and high (40%) in the A-tumour (Figure 1B).
A corresponding result is seen in the same microscopic areas of
the tumours stained for cyclin A (2 and 20%, respectively; compare
Figure 1A and C and Figure 1B and D). Image cytophotometric
S-phase analysis of Feulgen-DNA-stained cell nuclei in the near-
diploid D-tumour (Figure 1A and C) showed about 1% cells in
S-phase in contrast to 15% in the A-tumour (Figure 1B and D).
Figure 2 shows the direct quantitative relationship between Ki67
and cyclin A as proliferative markers. In Figure 2A, the percentage
of Ki67-positive cells is plotted against the percentage of cyclin
A-positive cells counted in the same 5–14 randomly selected
microscopic fields in each of four different tumours exhibiting
low, intermediate and high proliferative activity (Figure 2A). The
percentage of Ki67-positive cells was highly correlated (correlation
coefficient 0.88) with the percentage of cyclin A-positive cells,
when considering the same individual microscopic field in each of
the four tumours (Figure 2A). A large variation in proliferative
activity, in most cases two- to five-fold, was observed between the
different microscopic fields in each tumour. This emphasises the
importance of counting several different microscopic fields in each
tumour to get reliable quantitative information about proliferative
activity. When the analysis was performed in such a way on a set
of 428 tumours, a very high correlation (correlation coefficient
0.90) was found between percentage of Ki67-positive cells and
percentage of cyclin A-positive cells (Figure 2B). The data
presented in Figure 2B represent the average of 5–14 randomly
chosen microscopic fields in each tumour.
A comparison between D-tumours and A-tumours was
performed on 375 of the 428 tumours (Figure 2C and D). A
similar correlation between Ki67 and cyclin A was found in
tumours of both types, a correlation coefficient of 0.90 for the
D-tumours and 0.86 for the A-tumours. When comparing D- and
A-tumours with respect to proliferative activity, two features could
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sbe seen. On average, the proliferative activity was twice as high
in A-tumours (median value 21% Ki67-positive cells) as in
D-tumours (median value 11%). However, a very large overlap
in proliferative activity was found between these two groups. When
using a cut-off value of 15% for Ki67-positive cells (see further
Materials and Methods), the majority of the A-tumours (76%)
Tumour 861.98 Tumour 748.98
AB
CD
Figure 1 Ki67 (A and B) and cyclin A (C and D) immunostaining of the very same tumor areas of a slowly proliferating D-tumour (A and C) and a
rapidly proliferating A-tumour (B and D).
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Figure 2 Quantitative relationship between Ki67- and cyclin A-positive cells counted in the same 5–14 randomly selected microscopic fields in four
different tumours exhibiting low, intermediate and high proliferative activity (A), in a total of 428 tumours analysed in the same way (B) as well as in
D-tumours (C) and A-tumours (D) performed on 375 of the 428 tumours.
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sshowed high proliferative activity, whereas the majority of the
D-tumours (61%) showed low proliferative activity.
Image cytophotometric S-phase determination was performed
on the 375 ploidy analysed tumours. Although only about 100 cells
were analysed for each tumour, which is enough for the accurate
ploidy determination into D- or A-type, but probably insufficient
for accurate S-phase analysis, some information about SPF could
be obtained. Thus a lower, but still relatively good, correlation was
found between Ki67 and SPF (correlation coefficient 0.61) and
cyclin A and SPF (correlation coefficient 0.65).
A clearly increased risk of developing distant metastases is
seen when the proliferative activity increases (Figure 3). The same
result was obtained when either Ki67 or cyclin A was used as a
proliferative marker (Figure 3A and B). Among the tumours
with low proliferative activity, using a cut-off value of 15% for
Ki67-positive cells and 8% for cyclin A-positive cells (see further
Materials and Methods and Ahlin et al, 2007), between 5 and 10%
of all tumours had developed distant metastases during the 9-year
follow-up time (Figure 3A and B). Among the tumours with high
proliferative activity, between 25 and 30% of all tumours had
developed distant metastases during the same time period (Figure
3A and B). However, when taking node status and tumour size into
account, the role of proliferative activity as a risk factor becomes
more evident (Figure 4A–D). In node-negative (N0) tumours
smaller than 20mm (T1) in which the proliferative activity was
low, only 2–3% of the tumours developed distant metastases
during the 9-year follow-up time (Figure 4A and C). For node-
positive (Nþ), T1 tumours with low proliferative activity, the risk
of developing distant metastases had increased slightly to between
5 and 7% (Figure 4B and D). In tumours equal to or larger than
20mm (T2), the risk of developing distant metastasis had
increased somewhat further in the node-negative (N0) tumour
group to between 8 and 12% (Figure 4A and C), but substantially
in the node-positive (Nþ) tumour group to between 30 and 40%
(Figure 4C and D). In tumours of high proliferative activity, the
risk of developing distant metastases was considerably increased in
all tumour groups. For N0 tumours, the risk was between 20 and
25% (Figure 4A and C), and in Nþ tumours it was between 35 and
55% (Figure 4B and D).
An increased risk of distant metastases was also seen in the
highly aneuploid A-tumours as compared with the near-diploid
D-tumours (Figure 4). However, this increased risk could only be
demonstrated in small (T1), node-negative (N0) tumours, among
which the D-tumours exhibited a risk as low as 2–3% and the
A-tumours as high as 20–25% of developing distant metastases
(Figure 4E). For the remaining tumour groups T2N0, T1Nþ and
T2Nþ, no significant difference between D- and A-tumours could
be demonstrated (Figure 4E and F).
The relative contributions of genomic instability and proli-
ferative activity as risk factors for distant metastases became
very evident when the tumours were divided into four groups,
D-tumours with low proliferative activity (D low), D-tumours with
high proliferative activity (D high), A-tumours with low proli-
ferative activity (A low) and A-tumours with high proliferative
activity (A high), and also taking node status and tumour size
into account at the same time (Table 1 and Figure 5A). In the
group T1N0, all D-tumours, independently of proliferative activity,
showed a very low risk (less than 3%) of developing distant
metastases (Table 1 and Figure 5A). For the A-tumours in
the group T1N0, the situation was different. A-tumours with
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Figure 3 Relative risk of developing distant metastases independently of node status and tumour size when Ki67 (A) or cyclin A (B) was used as
proliferative marker.
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Figure 4 Relative risk of developing distant metastases in N0
(A, C and E) and Nþ patients (B, D and F) when Ki67 (A and B),
cyclin A (C and D) or ploidy type (E and F) was used as marker in T1 and
T2 tumours.
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slow proliferative activity, however, showed the same low risk
of developing distant metastases as the D-tumours, but for the
A-tumours with high proliferative activity, the risk of developing
distant metastases was found to be high (close to 30%) and
significantly increased (Po0.01) over that of the D-tumours with
high proliferative activity. This means that the A-tumours with
high proliferative activity metastasize very early, contrary to
D-tumours with high proliferative activity, and that the genomic
instability associated with the ploidy type A adds prognostic
information in addition to that of proliferative activity per se.
For large (T2) node-negative (N0) tumours, or small (T1) node-
positive (Nþ) tumours, the risk of distant metastases was only
moderately increased for tumours with low proliferative activity,
0–12% for the D-tumours and 13–17% for the A-tumours
(Table 1), again indicating that ploidy gives information in
addition to that of proliferative activity. Large (T2) node-positive
(Nþ) tumours were at high risk of metastasis relatively
independent of ploidy type or proliferative activity (Figure 5C
and Table 1).
By combining ploidy type (D or A), proliferative activity (low or
high), node-status (N0 or Nþ) and tumour size (T1 or T2), breast
cancers could be divided into two risk groups with respect to
development of distant metastases (Figure 5D). For the low-risk
group, consisting of all D-tumours in the T1N0 group together
with the A-tumours with low proliferative activity in the same
group plus all tumours with low proliferative activity in the T2N0
and T1Nþ groups, the risk of developing distant metastases was
less than 6%. For the high-risk group, consisting of all large (T2)
node-positive (Nþ) tumours and all tumours with high pro-
liferative activity, except the D-tumours in the T1N0 group, the
risk of distant metastases was found to be in the range 30–60%
(Figure 5C) and around 35% in average (Figure 5D). The low-risk
group defined in this way is relatively large and constitutes about
40% of all women with stage T1 and T2 breast cancer (Figure 5B).
By defining the low-risk group in a more stringent way, only
taking into account all the D-tumours in the T1N0 group plus the
A-tumours with low proliferative activity in the same group, the
low-risk group is still relatively large and now constitutes around
25% of all women with breast cancer. The risk of developing
distant metastases in this more stringently defined group is now as
low as around 2% (Table 1). Multivariate analysis showed that
proliferation (both Ki67 and cyclin A) was the most critical factor
in Nþ tumours (Po0.05) and ploidy was the most critical one in
N0 tumours (Po0.05).
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Figure 5 Relative risk of developing distant metastases in patients with T1N0 T2N0, T1Nþ and T2Nþ tumours of D- and A-tumour type showing low
and high proliferative activity using 15% Ki67 positive cells as cut off value (A). By combining ploidy type, proliferative activity, node status and tumour size
two breast cancer risk groups could be identified with respect to developing distant metastasis (B).
Table 1 Number and percentage of node-negative (N0) and node-positive (N+) T1 and T2 breast carcinomas with low or high proliferative activity
(Ki67/cyclin A) belonging to the D- or A-tumour type
Tumour size in N0 tumours Tumour size in N+ tumours
T1 n (%) T2 n (%) T1 n (%) T2 n (%)
Proliferation
Low (Ki67) 1/35 (2.86) 2/23 (8.70) 1/15 (6.67) 3/8 (37.50)
Low (cyclin A) 1/42 (2.38) 3/25 (12.00) 1/19 (5.26) 4/12 (33.33)
High (Ki67) 8/39 (20.51) 9/40 (22.50) 6/17 (35.29) 19/36 (52.78)
High (cyclin A) 8/32 (25.00) 8/38 (21.05) 6/13 (46.15) 18/32 (56.25)
Ploidy
D 1/36 (2.78) 3/17 (17.65) 3/12 (25.00) 9/18 (50.00)
A 8/35 (22.86) 7/34 (20.59) 4/17 (23.53) 10/22 (45.45)
Ploidy+proliferation
D+low (Ki67) 1/25 (4.00) 1/9 (11.11) 0/6 (0) 3/8 (37.50)
D+low (cyclin A) 1/32 (3.13) 1/8 (12.50) 0/9 (0) 2/8 (25.00)
D+high (Ki67) 0/11 (0) 2/8 (25.00) 3/6 (50.00) 6/10 (60.00)
D+high (cyclin A) 0/4 (0) 2/9 (22.22) 3/3 (100.00) 7/10 (70.00)
A+low (Ki67) 0/8 (0) 1/8 (12.50) 1/7 (14.29) 0/0
A+low (cyclin A) 0/7 (0) 2/10 (20.00) 1/8 (12.50) 2/4 (50.00)
A+high (Ki67) 8/27 (29.63) 6/26 (23.08) 3/10 (30.00) 10/22 (45.45)
A+high (cyclin A) 8/28 (28.57) 5/24 (20.83%) 3/9 (33.33%) 8/18 (44.44%)
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sDISCUSSION
In this study, it was found that both genomic instability and
proliferative activity can influence risk of developing distant metastases
independently of each other, and that they have different relative
impacts depending on tumour size and node status. One important
methodological aspect of the approach used in this paper is that the
Ki67 and the cyclin A analyses were carried out on identical
microscopic areas of each tumour. This is particularly important when
considering the large variations in proliferative activity that was found
to exist between different areas in the tumours. In addition to obtaining
accurate information about proliferative activity by using two
independent markers analysed in several identical microscopic areas
of each tumour, a direct quantitative comparison between the use of
Ki67 and cyclin A could also be performed in an accurate way. A
second important methodological aspect of this paper is that proli-
ferative activity and genomic instability could be studied simulta-
neously as independent risk factors in the same individual tumour.
This gives particular strength to the quantitative approach of this study.
The frequency of cyclin A-positive cells was highly correlated to
the frequency of Ki67 cells, both in the analysis of each individual
microscopic area and in the whole set of the 428 tumours. This
clearly shows that both Ki67 and cyclin A are equally reliable as
markers of proliferative activity. The average frequency value of
the cyclin A-stained cells was found to be about 0.4 times that of
the corresponding Ki67 values. As Ki67 is expressed throughout
most of the cell cycle (Gerdes, 1990), and the expression of cyclin A
is restricted to the S- and G2-phases in both normal and tumour
cells (Erlandsson et al, 2000), the data indicate that in breast
tumours the S- and G2-phases on average occupies about 40% of
the whole cell cycle as defined by Ki67.
A lower but still relatively good correlation was also found
between Ki67 and SPF and between cyclin A and SPF. The true
correlation is likely to be much higher taking into account the
large variation in proliferative activity seen between different
microscopic fields and the fact that the SPF was obtained from
cytophotometric measurements of only about 100 cells from just a
few microscopic fields in each tumour. Another factor that tends to
lower the correlation between SPF and Ki67 or cyclin A is the
overrepresentation of normal cells measured in the S-phase
analysis. This risk is, however, relatively low when SPF is based
on image cytometric analysis, in which only morphologically
identified cells are measured. For flow cytometric analysis, this
error in determining the SPF can be substantial, particularly in the
near-diploid tumours where all cells in the tumour are measured
without any possibility to make a discrimination between normal
and tumour cells on the basis of DNA content. For the clearly
aneuploid tumours, the admixture of normal cells in the tissue
sample can to some extent be estimated from the co-existence of
cells with diploid DNA values. However, a problem with the clearly
aneuploid tumours on the other hand is that some of the cells with
DNA values in the S-phase region may in fact represent non-
proliferating or growth-arrested cells with numerical chromosomal
aberrations. It is thus of decisive importance to be aware of these
difficulties when calculating SPFs from flow cytometry data
(Falkmer et al, 1990). In spite of these methodological deficiencies,
it has been shown that high SPF is a property that is related to poor
prognosis for many tumours (Kallioniemi et al, 1987).
In contrast to the interpretation of DNA histograms based on flow-
cytometric measurements, image cytometry based on DNA histo-
grams were preferentially interpreted by subdividing the histograms
in diploid or pseudo-diploid (D-tumours) and highly aneuploid
types (A-tumours) (Zetterberg and Esposti, 1980; Cornelisse et al,
1987; Fallenius et al, 1988a,b; Forsslund and Zetterberg, 1990;
Forsslund et al,1 9 9 6 ) .T h el a r g ed i f f e r e n c ei nt h ee x t e n to f
aneuploidy that exists between the highly aneuploid A-tumours on
one hand and the pseudo-diploid D-tumours on the other is most
likely generated by two principally different mechanisms. Evidence
has been obtained that a defective coordination between the centro-
some cycle and the DNA replication cycle leading to abnormal, often
tripolar, mitoses and highly unequal segregation of chromosomes
between daughter cells is crucial for the generation of high-degree
aneuploidy seen in the A-tumours (Kronenwett et al, 2005). The
low-degree aneuploidy seen in the pseudo-diploid D-tumours on the
other hand is more likely to be generated by some defect primarily in
the chromatid segregation mechanism at mitosis.
One of the main points of this paper was to quantitate the role of
g e n o m i ci n s t a b i l i t yo no n eh a n da n dp r o l i f e r a t i v ea c t i v i t yo nt h e
other as independent risk factors for the development of distant
metastases. The relative contributions of each of these two
risk factors became clearly evident first when the tumours were
divided into different subgroups with respect to ploidy type and
proliferative activity (D low, D high, A low and A high), and also
taking node status and tumour size into account at the same time.
Although increased proliferative activity in general was associated
with an increased risk of developing distant metastases, multivariate
analysis showed that ploidy level was an independent and even
stronger marker when considering small (T1) node-negative (N0)
tumours. In this group (T1N0), all D-tumours, independently of
proliferative activity, showed a very low risk of developing distant
metastases. This was also found for grade 1 tumours, although
histological grade in general was found to have less impact as risk
marker in comparison with proliferative activity and ploidy. For the
A-tumours in the same group (T1N0), the situation was different.
A-tumours with low proliferative activity showed about the same low
risk of developing distant metastasis as the D-tumours, but for the
group of A-tumours with high proliferative activity, the risk of
developing distant metastases was found to be high and significantly
increased over that of the D-tumours with high proliferative activity.
This means that the A-tumours with high proliferative activity
metastasise very early, contrary to D-tumours with high proliferative
activity. Thus the genomic instability associated with the ploidy type
A adds prognostic information that is independent of the proliferative
activity per se. Genomic instability is therefore likely to be a crucial
property in the process of forming distant metastases, and aneuploidy
per se as one mechanism of generating gene copy number imbalances
in the tumour is one important aspect of genomic instability. This is
further supported by our previous findings that chromosomal
rearrangements in terms of deletions, duplications and amplifica-
tions, as studied by CGH, were much more frequent in the highly
aneuploid breast tumours than in the pseudo-diploid ones (Blegen
et al, 2001). With high-resolution microarray-based CGH, we could
furthermore show that overall the degree of chromosomal rearrange-
ments as well as specific patterns of rearrangements were both related
to aggressive tumour behaviour (Hicks et al, 2006). Collectively, these
data clearly indicate that genomic instability is an important factor
for tumour progression and metastasis.
The possibility to classify breast tumours accurately into risk
groups on the basis of genomic instability together with
information about proliferation is an implication of practical
clinical relevance of this study. It is clear from the findings in this
paper that by combining ploidy type, proliferative activity and
tumour stage, a large group of low-risk breast tumours could be
identified, in which only a few percentage of the tumours
developed distant metastases. It is obvious that it would have
great practical implications when selecting patients for different
therapy regimes if risk of distant metastases could be predicted
objectively with high degree of precision.
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